Gabexate mesilate(FOY) is a serine protease inhibitor which has a inhibitory effect on the coagulation cascade in the absence of antithrombin III and it has been used for the treatment of DIC.
To evaluate the effect of Gabexate mesilate for the treatment of DIC 43 cases of neonatal DIC who were admitted to NICU of Pediatric department, Dong San hospital During the period from January 1990 to June 1992 were involved in this study. The
diagnosis of DIC was made by Shirahata's criteria.
Among 43 cases, 12 were treated with FOY (FOY group), 21 were with FFP( FFP group), and 10 were with vitamin K(Vit K group) Vit K group was used as control. Laboratory findings including platelef, PT, APTT fibrinogen before and after therapy, and
the
survival rate of each group were compared.
Age, gestational weeks, birth weight, and pretreatment laboratory findings had similar distribution in each group.
Pre-existed disease were prematurity(51%), pneumonia(23%), idiopathic respiratory distress syndrome(21%), intracranial hemorrhage(21%), congenital heart disease(21%), sepsis(16%), perinatal asphyxia(16%), necrotizing enterocolitis(14%), and
intrauterine
growth retardation(9%), and obstetric complications were existed in 65% of the cases. They has relatively even distribution in each group.
following therapy for 7 days, platelet, PT, APTT, and fibrinogen level were significantly improved in FOY and FFP groups than in Vit K group, and the survival rate of each group were 50% in FOY, 38% in FFP and 10% in Vit K group.
Therapy with Gabexate mesilate showed improving effect in the treatment of neonatal DIC than with FFP or Vitamin K.
|